Crescent Biopharma (CBIO) Competitors $13.29 +0.27 (+2.07%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesSEC FilingsSustainabilityTrendsBuy This Stock CBIO vs. GERN, ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, VSTM, and VNDAShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Geron (GERN), Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Geron Zenas BioPharma Regulus Therapeutics Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem Vanda Pharmaceuticals Geron (NASDAQ:GERN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership. Do insiders and institutionals have more ownership in GERN or CBIO? 73.7% of Geron shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 7.4% of Geron shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to GERN or CBIO? In the previous week, Geron had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Geron and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat Geron's score of 0.21 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, GERN or CBIO? Geron has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Which has higher earnings and valuation, GERN or CBIO? Crescent Biopharma has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M10.42-$174.57M-$0.21-6.00Crescent Biopharma$10K25,981.95-$37.88M-$46.00-0.29 Do analysts rate GERN or CBIO? Geron presently has a consensus price target of $4.61, suggesting a potential upside of 265.96%. Crescent Biopharma has a consensus price target of $25.67, suggesting a potential upside of 93.13%. Given Geron's higher probable upside, equities analysts clearly believe Geron is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Is GERN or CBIO more profitable? Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -119.54%. Geron's return on equity of -47.86% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Geron-119.54% -47.86% -26.78% Crescent Biopharma N/A -293.92%-206.20% SummaryGeron and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.82M$2.49B$5.70B$9.50BDividend YieldN/A1.65%4.58%4.00%P/E RatioN/A9.1828.3920.07Price / Sales25,981.95617.35427.4498.54Price / CashN/A165.2136.2258.56Price / Book1.615.168.675.88Net Income-$37.88M$30.99M$3.25B$258.89M7 Day Performance-0.37%7.73%4.30%3.70%1 Month Performance-21.36%16.27%10.57%11.71%1 Year PerformanceN/A-1.88%35.68%17.98% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma3.2028 of 5 stars$13.29+2.1%$25.67+93.1%N/A$259.82M$10K0.0050GERNGeron3.3658 of 5 stars$1.28+3.7%$4.61+261.7%-70.6%$805.70M$76.99M-6.0270Analyst RevisionGap DownZBIOZenas BioPharma1.6503 of 5 stars$14.30+0.1%$36.67+156.4%N/A$598.23M$15M-4.03N/ANews CoverageRGLSRegulus Therapeutics1.4848 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830LXRXLexicon Pharmaceuticals2.5612 of 5 stars$1.18-4.5%$3.67+212.1%-52.8%$424.75M$31.08M-2.30140Upcoming EarningsGap UpMYGNMyriad Genetics4.6751 of 5 stars$4.53+1.7%$14.38+217.9%-84.0%$417.12M$837.60M-4.042,700News CoverageEBSEmergent Biosolutions4.3376 of 5 stars$7.00+0.8%$14.33+104.9%-48.2%$379.69M$1.04B-2.582,420News CoveragePositive NewsRIGLRigel Pharmaceuticals3.3454 of 5 stars$20.10+2.6%$36.40+81.1%+85.0%$358.83M$179.28M9.70160Positive NewsXOMAXOMA Royalty4.0149 of 5 stars$25.65+0.6%$69.50+171.0%-10.7%$306.49M$28.49M-22.2710News CoverageAnalyst UpgradeVSTMVerastem3.526 of 5 stars$5.15+0.9%$13.38+160.0%+106.7%$282.72M$10K-1.6150VNDAVanda Pharmaceuticals4.7371 of 5 stars$4.70+0.8%$16.50+251.4%-22.9%$276.68M$198.77M-6.26290Upcoming Earnings Related Companies and Tools Related Companies Geron Competitors Zenas BioPharma Competitors Regulus Therapeutics Competitors Lexicon Pharmaceuticals Competitors Myriad Genetics Competitors Emergent Biosolutions Competitors Rigel Pharmaceuticals Competitors XOMA Royalty Competitors Verastem Competitors Vanda Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
